Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


8th World Nephrology Conference

Sao Paulo, Brazil

Carlos Alberto Tagliati

Carlos Alberto Tagliati

Universidade Federal de Minas Gerais School of Pharmacy, Brazil

Title: E-BABE-Renal cells as alternative methods for nephrotoxicity evaluation


Biography: Carlos Alberto Tagliati


Among hospital admissions due to acute kidney injuries, 20% are due to drug-induced nephrotoxicity. This stems from the fact that available in vivo methods (animal) are unable to reliably predict nephrotoxic effects. Only 7% of all new drugs fail in preclinical studies arising from the onset of nephrotoxicity, while the incidence of acute kidney injury in patients in Intensive Care Units is approximately 30-50%. Therefore, it is paramount the development of new techniques for in vitro models (which also reduce the use of animals) and low-scale analyses to determine toxicological profiles, aimed at improving the early diagnosis of the toxicity of new molecules. Nevertheless, due to the functional and biochemical heterogeneity of nephrons, susceptibility to toxicity can vary among nephron segments. Thus, it becomes necessary to use renal strains from different parts of nephron. Some cell lines, such as the LLC - PK1 (proximal tubule), MDCK (distal tubule) and BGM (a mixture of cells of proximal and distal tubules), have all been employed to evaluate nephrotoxicity. For this reason, interdisciplinary in related areas becomes essential in an attempt to apply mutual knowledge. In the Toxicology Biochemistry to be addressed in this study is the biochemical pathway involved in the context of pathophysiology. Gene expression also have demonstrated an important tool to identify new biomarkers. Using drugs such as Cyclosporine, Amphotericin B, Gentamicin and Cisplatin our results suggest this strategy have predictive value to identify early toxic effects, improving the selection of the candidate for the clinical stage.